Back to Journals » Neuropsychiatric Disease and Treatment » Volume 9

A critical review of the recent literature and selected therapy guidelines since 2006 on the use of lamotrigine in bipolar disorder

Authors Tränkner A, Sander C, Schönknecht P

Received 17 August 2012

Accepted for publication 27 September 2012

Published 18 January 2013 Volume 2013:9 Pages 101—111


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Anja Tränkner, Christian Sander, Peter Schönknecht

Department of Psychiatry and Psychotherapy, University Hospital Leipzig, Leipzig, Germany

Abstract: The anticonvulsant drug lamotrigine (LTG), a sodium channel blocker and inhibitor of glutamate release, has been found to have antidepressant effects in the treatment of bipolar disorder. It is recommended by certain therapy guidelines as a first-line agent for acute and maintenance therapy in bipolar depression, but there have been only some promising results of placebo-controlled trials on its acute antidepressant effects, and the recommendation in therapy guidelines has been reconsidered. On the contrary, positive results for maintenance therapy could be confirmed, and LTG is still a well-tolerated option, especially in patients with predominant depressive episodes. Antimanic effects are not shown in the literature, and its use is not advised in any guidelines that were examined. In conclusion, the findings of the present review article on treatment guidelines for bipolar disorder question the role of LTG in acute depressive states, and critically discusses its use, particularly in acute depressive states.

Keywords: lamotrigine, bipolar disorder, bipolar depression

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]